CD79A and autoimmune bullous skin disease: [33] additionally described the use of rituximab in a 43-year-old patient with a history of end-stage renal disease presenting with resistant linear IgA/IgG bullous dermatosis. Topical triamcinolone and two weeks of 60 mg oral prednisone did not provide resolution.